MGA Releases White Paper on Role of PBMs in US Drug Pricing Debate
MGA latest white paper, by CEO Alex Brill, looks at the role of pharmacy benefit managers (PBMs) in the US prescription drug market. The paper explains how these intermediaries provide value and draws lessons from past efforts to restrict PBMs, ultimately cautioning that targeting PBMs’ incentives and ability to negotiate lower prices with manufacturers could result in higher total drug spending.
Read the full paper here. More of MGA’s work can be found here.
